Pfizer (PFE) Stock Forecast & Price Target

$30.20

+1.02 (+3.50%)

(As of 10/9/2024 ET)

Pfizer - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
8

Buy
7

Based on 15 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 8 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for PFE.

Consensus Price Target

$34.54
14.38% Upside

According to the 15 analysts' twelve-month price targets for Pfizer, the average price target is $34.54. The highest price target for PFE is $45.00, while the lowest price target for PFE is $29.00. The average price target represents a forecasted upside of 14.38% from the current price of $30.20.

Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

PFE Analyst Ratings Over Time

Type	Current Forecast 10/10/23 to 10/9/24	1 Month Ago 9/10/23 to 9/9/24	3 Months Ago 7/12/23 to 7/11/24	1 Year Ago 10/10/22 to 10/10/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	11 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$34.54	$34.54	$35.69	$45.88
Forecasted Upside	14.38% Upside	17.48% Upside	24.54% Upside	38.32% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

Worker Strikes: Are You Prepared for What’s Coming? (Ad)

Worker Strikes: Are You Prepared for What's Coming? The rapid advancement of artificial intelligence and automation is reshaping industries and posing threats to jobs, pushing America's financial system to its limits.

Click here to prepare.

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pfizer Stock vs. The Competition

Type	Pfizer	Medical Companies	S&P 500
Consensus Rating Score	2.53	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	14.63% Upside	11,371.17% Upside	7.45% Upside
News Sentiment Rating	Positive News See Recent PFE News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/3/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$45.00 ➝ $45.00	+58.84%
8/7/2024	Daiwa America 0 of 5 stars	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy ➝ Strong-Buy
8/7/2024	Daiwa Capital Markets 1 of 5 stars		Upgrade	Neutral ➝ Outperform	$28.00 ➝ $34.00	+14.21%
7/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $32.00	+4.51%
7/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $30.00	-3.23%
7/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$30.00 ➝ $31.00	+0.23%
Get the Latest News and Ratings for PFE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.
5/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $29.00	+4.28%
5/2/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$33.00 ➝ $36.00	+30.62%
3/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/23/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$36.00	+30.67%
1/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$32.00	+7.67%
12/14/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$42.00 ➝ $36.00	+37.35%
10/16/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$42.00 ➝ $35.00	+3.80%
10/16/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$36.00 ➝ $34.00	+0.71%
10/16/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$38.00 ➝ $39.00	+21.46%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+38.66%
6/29/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$47.00 ➝ $40.00	+10.22%
4/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$50.00 ➝ $45.00	+12.92%
2/7/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$40.00	-8.24%
2/1/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform	$49.00 ➝ $48.00	+8.70%
2/1/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$50.00 ➝ $46.00	+4.17%
12/13/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chris Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$47.00 ➝ $60.00	+15.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 11:28 PM ET.

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 7, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

Here are some ways that investors could benefit from investing in Pfizer Inc.:

Pfizer Inc. reported earnings per share for the quarter that beat analysts' consensus estimates by $0.14, indicating strong financial performance.
Pfizer's revenue for the quarter was up 2.1% on a year-over-year basis, showing consistent growth in its top line.
Several hedge funds have been increasing their holdings in Pfizer, suggesting confidence in the company's future prospects.
Analysts have given Pfizer an average rating of "Moderate Buy" with a consensus price target of $34.54, indicating potential upside.
Pfizer's stock price has been trading up, showing positive momentum in the market.

Pfizer
Bear Case

Investors should be bearish about investing in Pfizer Inc. for these reasons:

Pfizer had a negative net margin of 4.66%, indicating lower profitability compared to some other companies in the industry.
The company's PE ratio is -486.83, which may raise concerns about its valuation and potential overvaluation.
Pfizer's debt-to-equity ratio of 0.65 may suggest higher financial leverage, increasing risk for investors.
The company's quick ratio of 0.60 may indicate potential liquidity challenges in the short term.
Pfizer's beta of 0.67 implies lower volatility compared to the market, which may limit potential returns for investors seeking higher risk-reward opportunities.

PFE Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $34.54, with a high forecast of $45.00 and a low forecast of $29.00.
: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 8 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PFE shares.
: According to analysts, Pfizer's stock has a predicted upside of 14.38% based on their 12-month stock forecasts.
: Over the previous 90 days, Pfizer's stock had 2 upgrades by analysts.
: Pfizer has been rated by research analysts at Barclays, Cantor Fitzgerald, Daiwa America, Daiwa Capital Markets, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Pfizer less than other "medical" companies. The consensus rating score for Pfizer is 2.53 while the average consensus rating score for "medical" companies is 2.79. Learn more on how PFE compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Bigger Than Nvidia? (Ad)

Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that's all they'll talk about.

Go here now for this breaking story.

This page (NYSE:PFE) was last updated on 10/9/2024 by MarketBeat.com Staff

From Our Partners